Article thumbnail

Predictive Factors for Prostate Cancer in Biopsy of Patients with Prostate-Specific Antigen Levels Equal to or Less Than 4 ng/ml

By Hyoung Woo Kim, Young Hwii Ko, Seok Ho Kang and Jeong Gu Lee
Topics: Original Article
Publisher: The Korean Urological Association
OAI identifier: oai:pubmedcentral.nih.gov:3065127
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. A multicenter study of the detection rate for prostate cancer according to the serum prostate-specific antigen level in Korean men.
  2. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer.
  3. Age-specific reference ranges for serum prostate-specific antigen in Korean men.
  4. Analysis of the clinicopathologic characteristics of men with prostate cancer undergoing radical prostatectomy in the prostate-specific antigen range of less than 4 ng/ml.
  5. Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels.
  6. Cancer surveillance series: interpreting trends in prostate cancer--part I: evidence of the effects of screening in recent prostate cancer incidence, mortality and survival rates.
  7. Comparison of the rate of detecting prostate cancer and the pathologic characteristics of the patients with a serum PSA level in the range of 3.0 to 4.0 ng/mL and the patients with a serum PSA level in the range 4.1 to 10.0 ng/mL.
  8. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening.
  9. Detection of prostate cancer in men with prostate-specific antigen levels
  10. Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical implications from Tyrol screening project. Urology 2005;66:1029-
  11. Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study.
  12. Impact of preoperative serum PSA level from 0 to 10 ng/mL on pathological findings and disease-free survival after radical prostatectomy.
  13. Lowering PSA cutoffs to enhance detection of curable prostate cancer.
  14. New thresholds for prostate-specific antigen velocity for prostate cancer screening in Korean patients younger than 60 years old.
  15. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter.
  16. Prostate cancer detection in Black and White men with abnormal digital rectal examination and prostate specific antigen less than 4 ng/ml.
  17. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
  18. Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/mL.
  19. Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL.
  20. PSA levels and the probability of prostate cancer on biopsy.
  21. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate.
  22. (1995). Repeat prostate needle biopsy: who needs it?
  23. Rising prostate cancer rates
  24. Screening for prostate cancer with prostate-specific antigen: beware the biases.
  25. Screening for prostate cancer.
  26. Screening with low PSA cutoff values results in low rates of positive surgical margins in radical prostatectomy specimens.
  27. (2005). The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of <4 ng/mL. Cancer
  28. Tumor markers as clinical cancer tests--are we there yet?
  29. (2004). Update on screening for prostate cancer with prostate-specific antigen. Crit Rev Oncol Hematol